Inhibikase Therapeutics (IKT) Cash & Equivalents (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Cash & Equivalents data on file, last reported at $49.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 32.5% year-over-year to $49.6 million in Q1 2026; TTM through Mar 2026 was $49.6 million, a 32.5% decrease from a year earlier, with the FY2025 full-year figure at $139.2 million, up 146.45% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $49.6 million, down from $139.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for IKT reached as high as $139.2 million in Q4 2025 and fell as low as $913420.0 in Q3 2024.
• Historically, Cash & Equivalents has averaged $32.5 million across 5 years, with a median of $14.9 million in 2023.
• Across the five-year window, Cash & Equivalents sank 94.09% in 2023 and jumped 4089.72% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $7.2 million in 2022, then grew by 27.5% to $9.2 million in 2023, then soared by 516.36% to $56.5 million in 2024, then surged by 146.45% to $139.2 million in 2025, then tumbled by 64.39% to $49.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $49.6 million in Q1 2026, $139.2 million in Q4 2025, and $38.3 million in Q3 2025.